My blog just published on @rheumnow. We need to screen for CV dz, educate pts about CVD and work with cardiology colleagues. https://t.co/XLc0YHtJ0B #ACR23

Using deep neural network for spinal inflammation in axial SpA, the area under the curve of the receiver operating characteristic (AUC-ROC) curve of the algorithm was 0.87±0.02, comparable with general radiologist Chan S et al Abst#1398 #ACR23 @RheumNow https://t.co/lrQRfc2RwN https://t.co/Fra8cDtQE5

Long-term safety of risankizumab in PsA and PsO pts Over 5k pts, over 4 years Rates of AEs remained low malignancy incidence remains low @RheumNow #ACR23 Abs#1422 https://t.co/GBFke3XmQD

@RheumNow So in GCA, we don’t know if therapies can truly disease modify at all. There’s a lot of grumbling disease, and it’s unclear whether we can stop long-term vascular issues. And in PMR, we have very little data on early therapy at all. So what’s the justification? #ACR23 @RheumNow https://t.co/spAMqfSOy2

This is pretty nerdy, but I would love a documentary about filgotinib JAK class wins/fails feel highly idiosyncratic to me The difference between UPA & FIL from science perspective seems negligible; financially, it's many billions of $$$ @rheumnow #ACR23 Abstr 1325 https://t.co/efGwSSrxz7

#ACR23 @RheumNow #GreatDebate Treatment for PMR by Spiera - Plan rapid GC taper. It is OK to flare, prepare pt! - Low threshold to introduce anti-IL-6 for GC intolerance or AEs No need for initial biologic treatment for PMR/GCA @philseo rebuttal upcoming... https://t.co/A0f3b0fMOr

Should IL-6i be first line in GCA/PMR? Dr. Spiera says steroids work, are cheap; no evidence of using IL6i early in disease. there had been cases where pts still had active vasculitis while on IL-6i. He starts with steroids first then add IL6i #GreatDebate #ACR23 @rheumnow https://t.co/Oq5Q9HFtW3

#ACR23 #Debate Dr Spiera says NO need to up front use #glucocorticoid #sparing drugs in PMR - maybe only if flaring. Esp in PMR vs #GCA where maybe bDMARD in GCA in some Pts (my opinion) but for sure if failing #ACRbest #ACR23 @RheumNow @ACRheum https://t.co/Rt7rGZv3fW

Towards Personalised Care in RA Since the millennium, we have seen an expansion in the number of advanced treatments both biologic and targeted synthetic disease modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis (RA). #ACR23 https://t.co/SjyfMyPyGw https://t.co/uzG72vKSpd

• Towards Personalised Care in Rheumatoid Arthritis | RheumNow

RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.

#ACR23 Abs #0844 posterior element inflammation & facet joint ankylosis on MRI uncommon in r-axSpA patients. However, when FJ inflammation is present (vs w/o) the likelihood of developing facet joint ankylosis after 1 year is over 3 x higher. https://t.co/1Kln1pNH3p @rheumnow https://t.co/BatNTFfTG2

Validation is needed, but SPARTAN + add'l stakeholders developed the first draft SPARTAN recommendations for referral of adults with chronic back pain to a rheumatologist for evaluation of axSpA! Check out #ACR23 Abs #0841 https://t.co/ISv2lgHyka @rheumnow https://t.co/Qvy8LlzOw0

When to use #belimumab and when to use #voclosporin? Dr. Dall'Era does the following: Belimumab: GFR<45, low proteinuria, extrarenal dz, pt factors Voclosporin: GFR>45 w/o sig chronicity, high level proteinuria (3+g/), pt preference for oral #ACR23 #MeetExpert @rheumnow https://t.co/0SXRBtChfk

"Get rid of partial response. Why would you want to see an oncologist who say I can get risk part of your cancer? Wouldn't you want to get rid of the whole cancer!" - Dr. M Petri on how we should view lupus nephritis #ACR23 @rheumnow #MeetExpert

Proof of concept for cCAR BCMA CD19 - safely eliminated all autoabs, reset B cell/humoral immune system, & delivered long-term, med-free remission in 1 dose in LN and SLE. More studies needed! #ACR Abs 1493 @rheumnow https://t.co/sT68cN3TKe